We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Clovis Oncology is stopping development of the lung cancer candidate rociletinib after the FDA warned the company of a potential complete response letter.